Jean-Pierre Sommadossi, Atea CEO

Covid-19 roundup: Atea Phar­ma­ceu­ti­cals launch­es an­tivi­ral in­to PhI­II tri­al; Cell­tri­on's an­ti­body shows promise against vari­ant

About a year af­ter jump­ing in­to the Covid-19 fight with its lead an­tivi­ral, Atea Phar­ma­ceu­ti­cals has launched a Phase III tri­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.